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Serum ferritin as a guide for iron stores in chronic hemodialysis
patients. The serum ferritin (SF) level was measured in 58 chronic
hemodialysis (CHD) patients (46 living and 12 deceased subjects) and
compared to bone marrow iron concentrations, cytological bone mar-
row iron stores (BMIS), and histological BMIS. In the 12 deceased
subjects, liver iron concentrations, histological liver parenchymal, and
Kupifer cell iron stores were also studied. The mean SF level of the
whole group was 302 251 ng/ml (mean SD). No close relationship
was found between transferrin saturation and cytological BMIS. A high
correlation was found between SF level and cytological BMIS (Spear-
man rank r, = 0.74). In the deceased CHD patients a close correlation
was observed between histological parenchymal liver iron stores and
histological Kupifer cell iron stores, but not between liver and bone
marrow iron stores. A good correlation was found between SF levels
and liver iron concentrations. It is concluded that in CHD patients SF
levels are higher than in healthy controls, even in the absence of iron
therapy (except in the form of blood transfusions); in some of these
patients iron is disproportionately stored in the bone marrow and the
liver. Although the level of BMIS cannot be estimated unequivocally
from an SF measurement in every CHD patient, SF levels provide
useful estimates of BMIS.
La ferritine sérique, un index des reserves martiales dans patients
hémodialysés chroniques. Chez 58 patients hémodialysés (dont 46 en vie
Ct 12 dhcédés) n'ayant recu aucun traitement au fer, nous avons
compare le taux de ferritine sérique (SF) avec les reserves de fer de Ia
moelle osseuse (BMIS) estimées par des niéthodes cytologiques,
histologiques et chimiques. Chez les 12 patients décédés, une étude
supplementaire de Ia concentration hépatique en fer fut effectuée, ainsi
qu'une estimation histologique des reserves en fer au niveau des
hépatocytes et des cellules de Kupifer. Sur l'ensemble de Ia population
étudiée, Ia SF fut de 302 251 ng/ml (nioyenne I écart-type).
Aucune relation directe entre Ia saturation de transferrine et les BMIS,
dCterminées par méthode cytologique, n'a pu Ctre démontrée. Entre Ia
SF et les BMIS, déterminées par méthode cytologique, ii existait une
correlation hautement significative (coefficient de correlation de Spear-
man, r, = 0.74). Chez les hemodialyses décédés, on a pu observer une
correlation significative entre les reserves martiales des hepatocytes et
des cellules de Kupifer, estimées histologiquement. Par contre, pas de
correlation significative n'a Pu Ctre démontrée entre les reserves
martiales hepatiques et médullaires (BMIS). Une excellente correlation
a été observée entre la SF et le dosage de fer tissulaire hépatique. On
peut en conclure que, par comparaison aux sujets normaux, Ia SF est
élevée chez les hemodialysés, méme en l'absence de toute
therapeutique martiale (a l'exception de transfusions sanguines); chez
certains de ces patients, les reserves en fer sont réparties de facon
inégale entre Ic foie et La moelle osseuse. Bienque Ia SF ne permette
point de determiner les taux de BMIS de facon non-équivoque chez
chaque patient hémodialyse, elle procure néanmoins un moyen
d'apprCciation simple et utile de ces BMIS.
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It is difficult to determine iron requirements in patients on
chronic hemodialysis (CHD). Some suffer from iron deficiency
due to chronic blood losses [11; others have increased iron
stores due to numerous blood transfusions. In healthy subjects,
Jacobs et al 121 found a positive relationship between the serum
ferritin (SF) level and iron stores estimated on the basis of
repeated venesections.
This finding in normal subjects has been extended to patients
with severe renal failure. Indeed, it has been argued by several
investigators [3—161 that SF levels can be used as a reliable
guide for iron therapy in CHD patients. This, however, may be
questioned because of the following considerations:
• First, in a number of pathological conditions (for example,
viral hepatitis), the SF level increases to levels disproportion-
ate to that of the iron stores [17].
• Second, normal values for the SF concentration have been
proposed in CHD patients [5, 7—10, 12, 14] that for un-
explained reasons, are higher than those of healthy individu-
als [2] and that vary considerably from one author to another.
The variable reference values may be due in part to differ-
ences in SF kits used [18, 19].
Since the bone marrow and the liver are the main iron storage
organs in healthy people, each accounting for about one third of
the total body iron stores (TBIS) [20], iron measurements of
these organs can be used to estimate the TBIS [21].
Furthermore, Gale, Torrance, and Bothwell [22] found a
close correlation between the semiquantitative histological
grading of bone marrow iron stores (BMIS) and the logarithm of
non-heme bone marrow iron concentrations. These correla-
tions, established in healthy subjects, have been extended by
many authors to CHD patients [3, 4, 7, 9, 12, 14, 16], and
cytological grading of the BMIS was used as the only parameter
in the evaluation of the TBIS.
All these considerations led us to re-evaluate the reliability of
the SF level as an indicator of iron stores in patients treated by
CHD.
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Methods
Patients. Two groups of patients with terminal renal failure in
CHD were studied. The first group consisted of 46 living
subjects, the second of 12 deceased subjects. Oral or parenteral
iron therapy had been administered to only two of the deceased
patients.
Procedures. Routine hematological and biochemical param-
eters were measured by standard techniques. Serum samples
for ferritin assay were drawn immediately preceeding a dialysis
session, and stored at —20°C until assay.
The SF level was assayed using a commercial method
(Gamma Dab® 125j Ferritin Radioimmunoassay kit, Clinical
Assays) using crystalline human liver ferritin. The standard
assay procedure was used (251d sample volume) [23]. The
manufacturer of the SF assay kit used in this study provides the
following reference values: 10 to 64 ng/ml for adult females less
than 45 years old, 24 to 155 ng/ml for females of 45 years and
above, 36 to 255 ng/ml for adult males less than 45 years old, 42
to 262 ng/ml for males of 45 years and above. In this study, the
reference interval used for CHD patients was 42 to 262 ng/mI.
The diagnosis of secondary hyperparathyroidism was re-
tained when bone histology showed clearly identifiable lesions
(extensive active osteoclastic resorption of bone and pro-
nounced bone marrow fibrosis) [24] in the presence of a
compatible biochemical profile (normo- or hypercalcemia, el-
evated serum C-terminal parathyroid hormone and elevated
serum alkaline phosphatase due to increased bone isoenzyme).
Bone biopsies (living and deceased subjects). Transiliac bone
biopsy specimens were taken 2 cm beneath and dorsal from
the anterior superior iliac spine with a 7-mm diameter trephine.
Bone marrow iron in reticuloendothelial (RE) cells was
semiquantitatively evaluated by two different observers in bone
marrow smears and in sections made from decalcified bone
biopsy specimens. The smears were fixed 10 mm in 100%
methanol and stained with the Prussian blue method [25].
The fixation and decalcification of the biopsies were per-
formed in two steps. First, the tissue sample was submerged in
B5 for 4 hr after the biopsy was performed (mercury chloride,
60 g/liter; sodium acetate, 12.5 g/liter; neutralized formaline
solution, 100 mI/liter; demineralized water up to 1000 ml). The
second step was fixation for at least 6 days in FE1O (an aqueous
solution composed of demineralized water, 800 ml;
Na2HPO4 2H20, 8.13 g; NaH2PO4 H20, 4 g; EDTA titriplex
III, 55 g; neutralized 37% formalin solution, 100 ml).
The bone sections were stained using the Prussian blue
method [25]. The cytological and histological iron stains were
graded for RE iron 0 to 6+ as proposed by Gale, Torrance, and
Bothwell [22]. In addition the bone marrow iron concentration
was determined in 31 patients (19 living and 12 deceased) using
atomic absorption spectrometry (AAS) [26]. Bone marrow
fragments (wet weight, 19.1 to 222.6 mg; median, 77.1 mg) were
prepared using a glass knife to cut off cortical bone. From 20 of
these 31 patients two bone marrow fragments were obtained for
chemical analysis and processed in different ways.
The first fragment was subjected to acid destruction. Using 5
ml concentrated nitric acid, the mixture was heated to 110°C
until a colorless residue was obtained. It was then diluted to 25
ml using bidistilled water. Finally the iron content was deter-
mined by injecting 10 d of this solution into the FIGA74
graphite furnace of an atomic absorption spectrometer (model
305B, Perkin Elmer, Norwalk, Connecticut). Iron concentra-
tion was calculated by means of two standard reference solu-
tions (0.5 and 1.0 g iron/ml in nitric acid 1%). The results were
expressed in milligrams of iron/lOO g of bone marrow (wet
weight).
The second bone marrow fragment, as well as a liver tissue
fragment, served to evaluate the contribution of hemoglobin to
total iron. This fragment was soaked in 5 ml of distilled water at
4°C for at least 2 days. The hemoglobin concentration was
determined in this solution by means of Crosby's technique
[27], and the iron concentration was measured using AAS.
Right and left-sided transiliac bone biopsy specimens were
taken from the deceased subjects and processed as above.
Liver biopsies (deceased subjects). The liver tissue samples
were stored in EA7O (denatured ethanol, 700 ml; demineralized
water, 300 ml) after fixation for 24 hr in AFA (denatured
ethanol, 850 ml; acetic acid, 50 ml; neutralized 37% formaline
solution, 1 dl). Liver sections were stained for iron using the
Prussian blue method [25]. Parenchymal and RE liver iron
(Kupifer cells) were graded separately (0 to 4+) as suggested by
Scheuer, Williams, and Muir [281.
Two fragments of unfixed liver tissue (stored at 4°C) were
used for total iron concentration determination. These tissue
specimens were ashed completely in a Tracerlab LTA 505
low-pressure ashing furnace. The residue was dissolved in 2 ml
of 1% nitric acid solution. In this solution the iron concentration
was measured using AAS [261 as above. In addition, a liver
tissue fragment was used to determine the contribution of
hemoglobin to total iron in the same way as for bone marrow
fragments.
Statistical analysis. Correlations were expressed by
Spearman's rank correlation coefficient (re). Paired observa-
tions were compared by the Wilcoxon signed rank test (left- and
right-sided iliac bone marrow iron concentrations, liver iron
concentrations).
Results
Table 1 gives the patient characteristics and pertinent he-
matological and biochemical data. The subjects were divided
into two groups of CHD patients: group 1, living subjects; group
2, deceased subjects.
In none of group 1 patients overt infection or inflammation
was present at the time of the bone biopsy. Eight of the living
and two of the deceased CHD patients were hepatitis B antigen
positive
Serum jer,-itin. The mean SF level was 302 251 ng/ml
(mean so. Ten patients presented SF levels below 42 ng/ml,
while in 28 subjects SF was 262 ng/ml or more.
Bone macrow im Table 2 gives the correlation coefficients
between the SF level, the bone marrow iron concentration, and
the cytological BMIS versus the amount of blood transfused
during the last year before biopsy, the quantity of serum iron,
the transferrin saturation (serum iron divided by total iron
binding capacity), the mean corpuscular volume (MCV), and
the blood hemoglobin level. No close correlations were ob-
served and most correlation coefficients were not significant.
Chemically determined bone marrow iron concentrations, in
right- and left-sided bone marrow biopsy specimens were
strongly correlated (r = 0.94, N = 12, P < 0.001). Hemoglobin
Serum ferritin in chronic hemodialysis 453
Group 2: Deceased patients, previously in CHD
2.1 M 60 CPN 39
2.2 M 22 CGN 30
2.3 F 62 CPN 31
2.4 F 64 Dia 10
2.5 M 56 0th 10
2.6 F 73 NAS 16
2.7 M 54 CPN 3
2.8 F 84 0th 3
2.9 F 64 CPN
2.10 M 53 CPN 7
2.11 F 52 0th 2
2.12 F 65 CPN 72
87 13 63 340 + 409
89 ND 30 160 + 38
94 ND 78 300 + 17
92 30 49 269 + 326
95 22 84 370 — 376
ND ND ND ND - 406
89 15 ND ND — 565
95 23 45 240 + 457
103 12 ND ND + 103
105 11 63 330 + 178
108 81 35 195 — >500
93 21 75 302 + >1000
Table 1. Clinical and biochemical features of living and deceased patients in chronic hemodialysis
Transfused
Time on blood last Serum iron TIBC Secondary
Patient Age CHD year Hb MCV Retic hyperpara- SF
no. Sex years Diagnosis months ml gidi fmoleslliter per ml p.g/dl thyroidism nglml
Group 1: Living patients in CHD
1.1 M 45 0th
1.2 M 30 Con
1.3 M 72 NAS
1.4 M 57 CGN
1.5 F 67 CPN
1.6 F 47 0th
1.7 F 26 CGN
1.8 M 49 CGN
1.9 F 51 CPN
1.10 F 55 CPN
1.11 M 52 Dia
1.12 M 59 CPN
1.13 F 45 PKD
1.14 M 60 CPN
1.15 M 60 NAS
1.16 M 50 NAS
1.17 M 41 CGN
1.18 F 56 NAS
1.19 M 71 CGN
1.20 M 36 CGN
1.21 F 43 NAS
1.22 M 64 CPN
1.23 F 57 CPN
1.24 M 32 Dia
1.25 M 74 NAS
1.26 F 30 Dia1.27 M 62 PKD
1.28 F 54 NAS
1.29 F 62 CPN
1.30 F 20 Con
1.31 M 46 CGN
1.32 F 66 CPN
1.33 F 65 CPN
1.34 F 68 CPN
1.35 M 59 PKD
1.36 F 46 CPN
1.37 F 76 CPN
1.38 M 70 Con
1.39 M 62 0th
1.40 F 63 CPN
1.41 F 70 PKD
1.42 M 71 Dia
1.43 M 70 CGN
1.44 F 26 0th
1.45 F 73 CPN
1.46 F 68 CPN
6 3420
27 450
2 0
18 7680
18 3590
6 500
6 400
3 0
17 3970
4 2240
6 400
36 6380
3 1190
15 970
4 1040
7 1870
7 2730
6 3150
2 350
6 400
89 800
24 750
60 450
10 1400
12 1350
14 5230
108 3000
6 2250
3 3420
7 2700
2 500
5 2250
71 0
2 2220
34 1350
72 950
54 450
9 4000
16 ND
1 900
10 0
24 4080
1 0
1 0
1350
24 450
86 5
99 14
97 21
88 11
101 34
85 15
83 ND
101 12
95 65
90 ND
73 18
92 15
86 25
86 16
91 38
101 20
88 19
91 17
95 16
91 8
94 29
76 11
95 14
80 18
93 16
94 38
93 6
94 20
96 2
99 6
98 14
89 22
93 21
93 49
88 17
96 16
94 5
100 ND
100 65
94 17
90 7
91 11
82 ND
89 32
88 27
92 10
26 326
80 293
19 214
197 360
72 375
80 310
60 390
75 345
85 330
85 390
40 315
62 340
40 315
45 270
47 345
80 280
72 228
78 212
39 218
55 272
41 265
30 346
35 228
48 417
78 268
43 269
59 218
105 259
194 249
184 228
74 312
122 302
75 302
106 282
87 500
43 295
68 302
103 269
84 306
35 232
46 349
61 269
30 389
39 292
35 151
63 218
— 500
+ 498
+ 145
+ 500
+ 500
+ 468
— 12
+ 145
+ 905
+ 166
— 24
+ 409
+ 10
+ 89
+ 109
+ 28
— 346
600
— 478
— 113
+ 500
— 5
+ 470
— 64
— 84
+ 198
+ 146
— 500
+ 183
— 616
— 48
+ 590
+ 1000
+ 636
— 18
+ 141
+ 166
+ 295
+ 246
+ 232
+ 41
— 26
+ 112
— 115
+ 347
341
5.9
12.7
8.7
6.1
9.1
6.2
7.5
8.0
6.9
9.6
10.0
7.2
9.3
7.1
9.3
10
11.6
8.5
7.6
8.9
9.9
8.9
8.0
8.9
8.9
5.5
8.9
10.9
8.2
11.3
11
6.8
10.8
8.8
10.4
9.0
12.9
8.4
6.9
5.5
9.6
9.4
10.7
9.9
5.2
8.3
6.8
6.2
6.8
8.3
9.3
9.9
10.3
12.4
7.8
8.6
11.3
10.8
9780
1400
1450
2680
2300
ND
ND
4300
520
5500
5630
ND
Abbreviations: CHD, chronic hemodialysis treatment; Hb, hemoglobin; MCV, mean corpuscular volume; Retic, reticulocyte count; TTBC, total
iron binding capacity; SF, serum ferritin; M, male patient; F, female patient; CGN, chronic glomerulonephritis; CON, congenital nephropathy;
CPN, chronic interstitial disease due to analgesic abuse, chronic nephritis; Dia, diabetic nephropathy; PKD, polycystic kidney disease; 0th, other
nephropathy; ND, not determined.
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SF level
Bone marrow
iron concen-
tration (AAS)
Cytological
BMIS
Blood transfused
during last year 0.34 (54) 0.15 (28) 0.33 (54)
Serum iron levels 0.31 (55) 0.06 (28) 0.26 (55)
Transferrin
saturation 0.44 (55) 0.17 (28) 0.35 (55)
MCV 0.25 (57) 0.15 (30) 0.23 (57)
Blood hemoglobin 0.01 (58) 0.15 (31) —0.04 (58)
given in parenthesis indicate the numbers of subjects
A
100F— I I I I I
0 1 2 3 4 5 6
Cytological grading of BMIS
Fig. 2. BMIS and SF. Relation between SF level and cytologically
graded BMIS (0 to 6+) in CHD patients (r, = 0.74, P < 0.001).
Symbols are: •, group I (N = 46); A, group 2 (N = 12). (For theA composition of the different groups, see Table 1).
for biopsy specimens graded 4 to 6. The trabecular iron content
• A of bone marrow biopsy specimens was estimated using the
A destruction procedure after repeated hypotonic submersions
and drying. The trabecular iron ranged from 2 to 13 mgIlOO g
bone marrow (wet weight), amounting to 18 to 20% of the total
bone marrow iron (N = 5).
A There is a good correlation between histological and cytologi-
• cal grading of BMIS (r = 0.81 P < 0.01). The relationship was
somewhat lower between bone marrow iron concentration and
cytologically graded BMIS (Fig. 1). Figure 2 gives the relationA between the SF level and the cytologically graded BMIS. The
A statistically significant correlation between the SF level and
cytological BMIS is apparent (r = 0.74, P < 0.001).
Liver iron. Total iron concentrations assessed in two liver
biopsy specimens of the deceased CHD patients showed a good
correlation (r = 0.97, N = 12, P < 0.001). The contribution of
hemoglobin iron to total liver iron concentration (N = 12)
ranged from 0.11 to 2.18 mg iron/l00 g tissue or 4.0% 3.5%
(SD),
There is also a good correlation (r = 0.93, N = 12) between
the histologically graded parenchymal liver iron content and the
total liver iron concentration (AAS). A relationship between
histologically graded Kupifer cell iron and total liver iron
concentration (AAS) was less evident (r = 0.78, N = 12).
Between the histological determinations of Kupifer cell and
parenchymal iron, a good correlation was found (r = 0.83).
Iron storage compartments and serum frrritin. Dispropor-
tionate iron storage in bone marrow and liver of some CHD
patients is evident from the comparison of the histologically
Table 2. Spearman rank correlation coefficientsr 1000 • • A
S
A
.
S
S
•
• S
•
•S.
S
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.
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10 ••
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a
aa
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0
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E
C0
a
Ca0C00
Ca
0
a
E
aCa 5
S
.
5•
.
S
I I
0 1 2 3 4 5 6
Cytological grading of BMIS
Fig. 1. Evaluation of BMIS. Relation between bone marrow iron
concentration (atomic absorption spectrometry) and cytologically
graded BMIS (0 to 6+) in CHD patients (r, 0.76, P < 0.001).
Symbols are: •, group I (N = 19); A, group 2 (N = 12). (For the
composition of the different groups, see Table 1).
40 F
20 I—
•
•
•A
2
••
A
S
0
iron was 29 22% (SD) of the total bone marrow iron as was
estimated in the bone marrow fragments subjected to prolonged
hypotonic submersion (N = 20). This mean value was 33% for
biopsy specimens with a cytological grading of 0 to 3, and 24%
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0 1 2 3 4 0 1 2 3 4
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Fig. 3. A and B. Comparison between histological BMIS (0 to 6+) and histological liver parenchymal iron content (0 to 4+) (A, r, = 0.21, P>
0.10) and histological Kupffer cell iron content (0104+) (B, r = —0.05, P> 0.10) in deceased CHD patients, Group 2 is noted by A (N = 12).
graded BMIS with the total liver iron concentration (r = 0.32,
N = 12), with the histologically graded parenchymal liver iron
(Fig. 3A), and with the histologically graded Kupifer cell iron
(Fig. 3B).
In the postmortem study, the SF levels show a good relation-
ship with cytologically graded BMIS (Fig. 4A) and with histo-
logically graded Kupifer cell iron content (Fig. 4B). In this
subject group, the SF levels show an even higher correlation
with total liver iron concentration (Fig. 4C) and with histologi-
cally graded liver parenchymal iron content (Fig. 4D).
Discussion
Reference values of SF levels
Variable reference values have been reported for SF levels of
CHD patients [5, 7—10, 12, 141. In this context, it should be
noted that different radioimmunoassays of SF yield different
results [18, 19]. Depending on the specificity of the antisera, SF
level measurements of one sample may vary by as much as
fourfold [191. However, a close linear correlation exists be-
tween the results of SF determinations using different com-
mercial kits in CHD patients [18]. Consequently, relationships
between iron stores and SF levels determined with one of these
kits are also valid for the others. We have used the normal
reference values given by the kit manufacturer for males of 45
years or more, to avoid underscoring of the number of patients
with decreased iron stores or overscoring the number with
increased iron stores. In contrast to healthy individuals, male
and female CHD patients show no obvious reasons for having
distinct SF values [11].
Relationship of SF levels to BMIS in living CHD patients
The SF level, considered as a parameter of iron storage in
CHD patients [3—9, 12, 14, 16], has been proposed as a useful
guide for establishing iron requirements [3, 6—11, 13—16]. This
has been questioned, however, by some authors, because of
difficulties in estimating TBIS.
Most often, the BMIS are used as an estimate of the TBIS,
because the BMIS make up one-third of the TBIS in healthy
subjects and because the bone marrow is readily accessible.
However, in some CHD patients iron may be stored dis-
proportionately in different organs and discrepancies may exist
between the SF level and the BMIS [29]. Also, many factors,
such as viral hepatitis, inflammatory disease, and blood trans-
fusions (which are frequently given to CHD patients) have
greater influence on the SF level than on the iron stores [17].
The results of a preliminary study indicating normal SF levels
without visible RE iron in some patients [30] led us to re-
evaluate the SF criteria in CHD patients.
In our study, although the grading system comprised seven
grades (0 to 6+), good agreement between semiquantitative
cytologic and histologic grading of the BMIS was observed
despite differences in sample processing. Only a few subjects
with pronounced myelofibrosis had cytologic and histologic
grading differences of two or more.
The relationship between cytological BMIS and the chemical
measurement of total bone marrow iron concentration was less
apparent especially in the subjects with low marrow iron
concentrations (Fig. I). Several explanations of this observa-
tion are possible: contamination of the samples with iron,
66
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Histologically graded liver
parenchymal iron content
Histologically graded Kupifer
cell iron content
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inaccuracy of the chemical method, nonhomogeneity of iron
distribution in bone marrow, and the three-compartmental
distribution of iron in bone marrow (that is, heme iron,
trabecular iron, and RE iron). Immersion of bone marrow
biopsy specimens in water and measurement of the liberated
iron and hemoglobin showed that the contribution of heme iron
to total iron was not negligible, obviously in biopsy specimens
with low total iron content.
All these findings suggest that both cytohistologic grading and
chemical measurement of total iron concentration are fairly
accurate measurements of different bone marrow iron compart-
ments. The distribution of iron in these compartments in CHD
patients needs further study.
We found a significant correlation between SF levels and
cytohistologic BMIS that has been reported in the literature [3,
5, 7, 9, 12, 14, 16]. In some of the individuals reported,
however, the SF level can be misleading, when used as an index
of BMIS (Fig. 2).
Our results also confirm that SF levels are higher in CHD
patients as compared to healthy individuals [3—5, 7, 10, 12, 141.
Twenty-eight of the 58 patients showed SF levels above normal.
One explanation could be the occurrence in these subjects of
infection, liver disease, or blood transfusions [17]. In our CHD
patient group, the frequency of infection or liver disease was
low. Another explanation for these high SF levels could be the
elevated bone marrow RE iron grades in CHD patients when
compared to a control population [31].
Although almost none of our subjects had received iron
therapy (except in the form of blood transfusions) in the year
preceeding the onset of the study, SF levels below 42 ng/ml
were seen in only ten patients (Fig. 2). All these patients except
one showed low cytological BMIS (grade 0 to 1 +), indicating
that, at least in this group, the SF level appeared to be a good
parameter for detecting low BMIS. However, in 6 of the 15
patients with low cytological BMIS (0 or I +), the SF levels
were higher than 42 ng/ml. Thus, a low SF level indicates low
BMIS; however, almost half of the patients with low BMIS
have SF levels considered to indicate replete iron stores.
Raising the diagnostic threshold of the SF level for CHD
patients, as proposed by some authors [9, 13, 14], can only
partially overcome the problem. Raising the normal lower limit
from 42 ng/ml up to, for example, 80 ng/ml, reduces the number
of patients with low cytological BMIS and SF levels higher than
the limit, from 6 to 5.
Raising the normal lower limit further up to, for example, 150
ng/ml, further reduces the number of patients with low cytologi-
cal and SF levels above the lower limit, to only 2. However,
nine patients with normal cytological BMIS also show SF levels
below 150 ng/ml.
Most of the patients with low BMIS did not manifest the
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Histologically graded liver
parenchymal iron content
1000
100
1010 L
A
A
A
1 10 100 500
Total liver iron concentration,
my iron/IOU g wet tissue
Fig. 4. A, B, C, and D. SF level in relation to cy-
tological grading of BMIS (A r, = 0.84, P <
0.01), to histologically graded Kupffer cell iron
content (B r1 = 0.83, P < 0.01), to total liver
iron concentration (C r, = 0.94, P < 0.001), to
histologically graded liver parenchymal iron con-
tent (D r, = 0.95, P < 0.001) in deceased CHD
patients (N = 12). Group 2 is noted by A (N =
12).
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classical symptoms of iron deficiency anemia as defined by
Bainton and Finch [32], which may indicate that a low BMIS is
not a limiting factor in red cell production in most CHD
patients.
In the CHD patient group with increased cytologic BMIS
(grade 4 + or more), only 5 out of 32 patients showed SF levels
below the upper normal limit and SF levels were above normal
in all ten patients with excessive cytologic BMIS (grade 6+).
Again, SF levels rarely underestimate BMIS.
Relationship of SF levels to BMJS and to liver iron stores in
deceased CHD subjects
Since the relationship between BMIS and TBIS is not clearly
delineated in CHD subjects [29], bone marrow and liver iron
were compared in 12 deceased CHD subjects. The choice of the
liver as an additional indicator of TBIS was obvious, since the
liver accounts for another one-third of the total amount of
stored iron in healthy individuals [20]. Liver iron was studied
histologically and chemically to estimate both its distribution as
well as its concentration among parenchymal and Kupifer cells.
According to the histological gradings, the importance of these
two liver iron compartments is comparable in the studied CHD
patients.
Minor discrepancies may depend on the route of iron admin-
istration: Iron administered intravenously is preferentially
stored in Kupifer cells [30], while orally administered iron is
preferentially stored in parenchymal liver cells carrying trans-
ferrin receptors.
There is a correlation between the bone marrow and liver iron
concentration [33]. However, in some patients there exists a
preferential storage of iron in the bone marrow RE cells (Fig. 3),
which may be related to the presence of renal osteodystrophy
and which contrasts with observations in healthy individuals,
who show proportionate iron storage in the bone marrow and in
the liver [22].
Looking at the correlation between SF levels and reticuloen-
dothelial (bone marrow RE cell and liver Kupifer cell) versus
liver parenchymal iron stores, the relationship between the SF
level and the liver parenchymal iron stores (Fig. 4C and D) is at
least as good as that between SF and reticuloendothelial iron
stores (Fig. 4A and B). This observation argues against the
hypothesis that SF only originates in RE cells [341 and supports
the view of other authors who consider parenchymal cells also
to be an important source of SF [35].
In view of the difficulties involving the measurement of the
TBIS, the exact relationship of the SF level with this parameter
in CHD patients has yet to be defined. The value of the
relationship between SF levels and iron stores in guiding iron
therapy is still problematic. Comparing our results with deter-
minations of BMIS in normal individuals [31], we note that RE
iron overload appears to be common in CHD, which serves as
an argument against systematic administration of iron to CHD
patients and especially those being transfused. Indeed, in most
patients with CHD, the administration of blood to treat anemia
unrelated to iron deficiency or as part of a pretransplant
program provides sufficient amounts of iron to satisfy iron
needs, making supplementary iron therapy unnecessary and
potentially dangerous [30, 36]. Nevertheless, iron depletion
should be anticipated in CHD patients who are not transfused
and not receiving iron therapy or in CHD patients who present
a SF level below 42 ng/ml.
It is concluded that SF rarely underestimates and frequently
overestimates bone marrow storage iron and that bone marrow
and liver iron stores correlate closely with SF levels.
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